Selpercatinib (Retevmo) — RET-Driven Lung & Thyroid Cancer | GLT

Generic Info

Selpercatinib, marketed under the brand name Retevmo, is an oral, highly selective RET kinase inhibitor developed by Eli Lilly and Company (via Loxo Oncology). The U.S. FDA first approved Retevmo in 2020, making it the first therapy specifically indicated for RET-driven cancers. It is supplied as 40 mg and 80 mg capsules and 40/80/120/160 mg tablets.

What Is Selpercatinib Used For?

Selpercatinib is used to treat cancers driven by RET gene alterations: RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), RET fusion-positive thyroid cancer, and other RET fusion-positive solid tumors. It is prescribed only after a molecular test confirms the presence of a RET fusion or mutation.

How Does Selpercatinib Work?

RET is a receptor tyrosine kinase that, when altered by a gene fusion or mutation, drives uncontrolled cancer cell growth. Selpercatinib is a highly selective RET kinase inhibitor: it binds and blocks RET, shutting down downstream signaling that fuels tumor growth. Because it crosses the blood-brain barrier, it is effective against brain metastases. In the LIBRETTO-001 trial, 10 of 11 previously treated NSCLC patients with measurable brain metastases showed intracranial responses.

Indications

• RET fusion-positive locally advanced or metastatic NSCLC
• RET-mutant advanced or metastatic medullary thyroid cancer (MTC)
• RET fusion-positive advanced or metastatic thyroid cancer (radioactive iodine-refractory, when applicable)
• RET fusion-positive locally advanced or metastatic solid tumors

Dosage

The recommended dose in adults and adolescents 12 years and older is based on body weight: 120 mg orally twice daily for patients under 50 kg, and 160 mg orally twice daily for patients 50 kg or greater, until disease progression or unacceptable toxicity. Dose reductions are required for severe hepatic impairment.

Side Effects

The most common side effects of selpercatinib include dry mouth, diarrhea, hypertension, fatigue, edema, constipation, rash, and elevated liver enzymes (ALT/AST). Serious side effects include hepatotoxicity, interstitial lung disease (ILD)/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, and hypersensitivity reactions. Liver function and blood pressure should be monitored regularly during treatment.

Storage

Store selpercatinib at room temperature (20°C to 25°C / 68°F to 77°F). Keep in the original container, tightly closed, and out of reach of children. Do not use after the expiration date printed on the package.

Why Choose the GLT?

GIVE LIFE TIME LIMITED (GLT) sources genuine, manufacturer-sealed Retevmo (selpercatinib) and ships internationally with reliable logistics. We support both institutional buyers (hospitals, pharmacies, distributors) and individual patients, with responsive customer service and clear ordering guidance throughout the process.

How to Order

Contact our team via WhatsApp or email to confirm current availability, pricing, and shipping options for your region. Provide the required strength and quantity, and we will guide you through the ordering and delivery process.

FAQ

Q: Is Retevmo a chemotherapy?
No. Selpercatinib is a targeted therapy (a RET kinase inhibitor), not a conventional chemotherapy.

Q: Who can take Retevmo?
It is for patients whose cancer has a confirmed RET gene fusion or RET mutation, as detected by a molecular test.

Q: How is Retevmo taken?
It is taken orally, twice daily, with the dose based on body weight (120 mg or 160 mg twice daily for adults).